Potential liver toxicity in diabetics using Rezulin (troglitazone)

January 1998

There's a growing concern about potential liver toxicity in diabetics using Rezulin (troglitazone).

Rezulin has been given to over half a million patients since it came out early last year.

But now there are over 150 reports of possible liver dysfunction...resulting in one liver transplant and several deaths.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Evista (raloxifene), the new "designer estrogen"
Hair Loss Two new treatments for hair loss
Interactions Significant interaction between Buspar (buspirone) and erythromycin or itraconazole
Migraine Zomig (zolmitriptan for migraines
Migraine Migranal, a new Nasal Spray for migraines
Migraine Stadol (butorphanol) is finally a federally controlled substance (C-IV)
Two new DRY POWDER inhalers will soon hit the market
Cholesterol Mevacor (lovastatin) seems to reduce the risk of heart attack
Cholesterol Baycol (cerivastatin) from Bayer
Cholesterol Switch from one statin to another
Oral Health Aphthasol (amlexanox oral paste), the first Rx drug approved for aphthous ulcers or canker sores
Diabetes Potential liver toxicity in diabetics using Rezulin (troglitazone)
Diabetes Stop making Iletin I (beef/pork) insulin this year
Diabetes Monitor Long-Term blood sugar control at home
Hematology & Oncology Neumega (oprelvekin) to stimulate the production of platelets
Hematology & Oncology The first monoclonal antibody for cancer
Cardiology Plavix (clopidogrel) to prevent recurrent heart attacks or ischemic strokes
Milk thistle to prevent liver toxicity
Practice Annual new drug chart for 1997